 This study found that enocetylcysteine, NISI, had no significant effect on the serum level of lipoprotein A, LPA, in type 2 diabetic patients with diabetic nephropathy. However, NAC did reduce the amount of proteinuria, serum triglyceride, TG, level and systolic blood pressure in these patients. Further research is required to fully understand the potential benefits of NAC in treating type 2 diabetic patients with nephropathy. This article was authored by Hamid Rohi and Faruzan Ganji.